7427.TWO Great Novel Therapeutics Biotech & Medicals
- Market cap
- TWD 3.08B
- P/E
- -
- P/B
- 4.30x
- ROE
- -19.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 7427.TWO undervalued?
Graham numberThe Graham number of Great Novel Therapeutics Biotech & Medicals cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Great Novel Therapeutics Biotech & Medicals fundamental analysis
No fundamental analysis for Great Novel Therapeutics Biotech & Medicals yet.
Great Novel Therapeutics Biotech & Medicals stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Great Novel Therapeutics Biotech & Medicals
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan. The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity. I…
Full company profileGreat Novel Therapeutics Biotech & Medicals financial statements
Great Novel Therapeutics Biotech & Medicals annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | - | 630K | 540K | 4.85M | 1.69M | 1.21M |
| Gross Profit | - | -939K | 283K | 464K | 4.81M | 1.02M | -1.18M |
| Operating Income | - | -42.9M | -36.5M | -57.4M | -65.8M | -113M | -99.5M |
| EBITDA | -28.9M | -43.4M | -35.1M | -54.0M | -54.9M | -97.9M | -89.7M |
| Net Income | -29.9M | -31.3M | -35.9M | -55.8M | -61.5M | -105M | -97.5M |
| EPS | -2.20 | -1.97 | -1.70 | -2.31 | -1.70 | -2.55 | -2.18 |
| Balance Sheet | |||||||
| Total Assets | 85.7M | 126M | 230M | 373M | 645M | 663M | 527M |
| Total Liabilities | 18.7M | 5.30M | 21.6M | 12.0M | 26.8M | 29.3M | 23.8M |
| Shareholders' Equity | 67.0M | 121M | 208M | 361M | 618M | 633M | 503M |
| Cash & Short-term Investments | 13.5M | 67.0M | 125M | 248M | 477M | 583M | 29.8M |
| Total Debt | - | 76.0K | 860K | 833K | 14.4M | 10.5M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -18.5M | -41.9M | -33.9M | -65.8M | -55.0M | -76.8M | -87.6M |
| Capital Expenditure | 0.00 | 13.1M | 28.0M | 12.6M | 2.93M | 3.46M | 3.49M |
| Free Cash Flow | -18.5M | -55.0M | -61.9M | -78.4M | -57.9M | -80.3M | -91.1M |
| Ratios | |||||||
| ROE | -44.6% | -25.9% | -17.2% | -15.5% | -10.0% | -16.6% | -19.4% |
| ROA | -34.9% | -24.8% | -15.6% | -15.0% | -9.5% | -15.8% | -18.5% |
| Net Profit Margin | - | - | -5,691.6% | -10,329.4% | -1,268.9% | -6,226.9% | -8,089.0% |
| Debt to Equity | - | 0.00x | 0.00x | 0.00x | 0.02x | 0.02x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Great Novel Therapeutics Biotech & Medicals dividends
Great Novel Therapeutics Biotech & Medicals has not paid dividends in the last 7 fiscal years.
Who owns Great Novel Therapeutics Biotech & Medicals
Ownership data of Great Novel Therapeutics Biotech & Medicals is not available yet.
Great Novel Therapeutics Biotech & Medicals company profile
- Company name
- Great Novel Therapeutics Biotech & Medicals
- Ticker
- 7427.TWO
- ISIN
- TW0007427007
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Fiscal year end
- December
- Address
- No.508, Zhongxiao East Road, Taipei, Taiwan, 115
- Phone
- 886 2 2785 1399
- Website
- gntbm.com.tw
About Great Novel Therapeutics Biotech & Medicals
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan. The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity. It is also developing Kepida to treat HR+/her-2 advanced breast cancer and Peripheral T-cell lymphoma. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was incorporated in 2013 and is based in Taipei, Taiwan.
Great Novel Therapeutics Biotech & Medicals management
4- Dr. Chia-Nan ChenPresident & Chairman of the Board
- Ms. Yi-Hua WuFinancial & Accounting Manager
- Ms. Pei-Ching HsuDirector of Administration Department
- Mr. Jia Xiong ChenAssistant Director of New Drug R&D Center and Director